Harrow, Inc.

NasdaqGM:HROW Stock Report

Market Cap: US$1.9b

Harrow Management

Management criteria checks 2/4

Harrow's CEO is Mark Baum, appointed in Apr 2012, has a tenure of 13.67 years. total yearly compensation is $1.36M, comprised of 53.8% salary and 46.2% bonuses, including company stock and options. directly owns 8.06% of the company’s shares, worth $149.78M. The average tenure of the management team and the board of directors is 0.9 years and 2.8 years respectively.

Key information

Mark Baum

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage53.82%
CEO tenure13.7yrs
CEO ownership8.1%
Management average tenureless than a year
Board average tenure2.8yrs

Recent management updates

Recent updates

Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS

Dec 01

Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump

Oct 03
Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump
User avatar

VEVYE And TRIESENCE Programs Will Expand Prescription Access

Harrow is focusing on boosting sales and profitability through patient affordability programs, strategic supply chain improvements, and next-gen product developments.

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29

Harrow: A Name I Am Accumulating

Mar 19

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Mar 01

Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price

Feb 17
Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price

Harrow: The Triesence Relaunch

Dec 14

Harrow: Spotlight On IHEEZO

Nov 16

Harrow's Focus - Reviving Old Drugs In A Crowded Market

Oct 02

Harrow: 3 Business Models, One Mission

Sep 10

Borrowing Cash To Burn It: The Curious Case Of Harrow

Aug 21

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom

May 02

Harrow's Drug Iheezo Is Off To A Great Start

Feb 19

Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity

Jan 30

Harrow sells non‑ophthalmic compounding business, terms undisclosed

Oct 05

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

Sep 27

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Aug 19

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Aug 11
These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

May 23

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

May 12
Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Mark Baum's remuneration changed compared to Harrow's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$5m

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$22m

Dec 31 2024US$1mUS$731k

-US$17m

Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$34m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$15mUS$680k

-US$24m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$609k

-US$14m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$21m

Dec 31 2021US$7mUS$565k

-US$18m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

US$10m

Dec 31 2020US$2mUS$570k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$1mUS$489k

US$168k

Sep 30 2019n/an/a

US$16m

Jun 30 2019n/an/a

US$25m

Mar 31 2019n/an/a

US$29m

Dec 31 2018US$1mUS$411k

US$15m

Compensation vs Market: Mark's total compensation ($USD1.36M) is below average for companies of similar size in the US market ($USD5.45M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Baum (53 yo)

13.7yrs
Tenure
US$1,358,490
Compensation

Mr. Mark L. Baum, J.D., Co-founded Harrow Health, Inc. (formerly, Imprimis Pharmaceuticals, Inc.) and has been Chief Executive Officer since April 1, 2012 and serves as Chairman of the Board since August 1...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Baum
CEO & Chairman of the Board13.7yrsUS$1.36m8.06%
$ 149.8m
Andrew Boll
President10.8yrsUS$849.20k2.19%
$ 40.7m
Randall Pollard
Chief Accounting Officerless than a yearno datano data
Amir Shojaei
Chief Scientific Officerless than a yearno datano data
Michael Biega
Vice President of Investor Relations & Communicationsless than a yearno datano data
Brett Burrell
Vice President of Legal & Compliance2.2yrsno datano data
Kim Barratt
Chief Talent Officerno datano datano data
Mark Mannebach
Head of Regulatory Affairs & Pharmacovigilance2.8yrsno datano data
Greg DiPasquale
Senior VP & Head of Commercial1.6yrsno datano data
Prashanth Annavajjhala
Chief of Staffless than a yearno datano data
Patrick Sullivan
Head of Commercialless than a yearno datano data
Vincent Mair
Senior Vice President of Commercial Operationsless than a yearno datano data
0.9yrs
Average Tenure
53yo
Average Age

Experienced Management: HROW's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mark Baum
CEO & Chairman of the Board14yrsUS$1.36m8.06%
$ 149.8m
Adrienne Graves
Independent Director1.9yrsUS$260.29k0.031%
$ 575.2k
Lauren Silvernail
Independent Director1.9yrsUS$257.79k0.031%
$ 575.2k
Perry Sternberg
Lead Independent Director3.8yrsUS$252.50k0.079%
$ 1.5m
2.8yrs
Average Tenure
61.5yo
Average Age

Experienced Board: HROW's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 00:55
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Harrow, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG
Steven SeedhouseCantor Fitzgerald & Co.